Mutants of bone morphogenetic proteins

Details Mutants of bone morphogenetic proteins Mutants of bone morphogenetic proteins

2008-05-27

2008-05-27

Rao, Manjunath (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S399000

Reexamination Certificate

active

11452550

ABSTRACT:
The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention related to novel mutants containing only the entire region involved in the formation of finger 2 including the wrist epitope of a BMP with a specific cysteine residue or specific cysteine residues replaced by a different amino acid. The present invention also relates to pharmaceutical compositions containing these mutants and to methods for using the mutants and pharmaceutical compositions in therapy.

REFERENCES:
patent: 7186689 (2007-03-01), Weber
patent: WO 99/61611 (1999-12-01), None
patent: WO 00/17360 (2000-03-01), None
patent: WO 00/20449 (2000-04-01), None
patent: WO 01/11041 (2001-02-01), None
Wozney et al., Science. Dec. 16, 1988;242(4885):1528-1534.
Information Hyperlinked Over Proteins, BMP4.
Barlow et al., Development. Jan. 1997;124(2):391-8, Abstract Only.
Jane et al., Mol Ther. Oct. 2002;6(4):464-70, Abstract Only.
Kishimoto et al., Bone. Aug. 2002;31(2):340-7, Abstract Only.
Weber et al., J Bone Miner Res. Dec. 2003;18(12):2142-51.
Wilde et al., Drugs. Oct. 1997;54(4):597-614.
Calin et al., Eds., The Spondylarthritides. Oxford University Press. New York. 1998. pp. 27-30.
O'Connor et al., Clin Orth and Rel Res. 1998;346:71-80.
Karsenty et al., Genes Dev. Dec. 1, 1999;13(23):3037-51.
Baysal et al., Eur Radiol. 1998;8(3):479-81.
Kirsch et al., “BMP-2 Antagonists Emerge from Alterations in the Low-Affinity Binding Epitope for Receptor BMPR-II,” 19(13):3314-3324, 2000.
Marker et al. “Spectrum of Bmp5 Mutations from Germline Mutagenesis Experiments in Mice,”Genetics, 145(2):435-443, 1997.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., Eds., Birkhauser, Boston, MA, (1994) pp. 433-506.
Nickel et al., “The Crystal Strucutre of the BMP-2:BMPR-IA Complex and the Generation of BMP-2 Antagonists,”J. Bone and Joint Surgery, 83-A(Supp. 1)(No. Pt. 1):S7-14, 2001.
Gelbart, “The decapentaplegic gene: a TGF-beta homologue controlling pattern formation in Drosophila,”Development, 107 Suppl:65-74 (1989).
Scheufler et al., “Crystal Structure of Human Bone Morphogenetic Protein-2 at 2.7 Å Resolution,”J. Mol. Biol., 287:103-115 (1999).
Weber et al., “Disulfide Bridge Conformers of Mature BMP Are Inhibitors for Heterotopic Ossification,”Biochem. and Biophys. Res. Comm., 286:554-558 (2001).
Wolring et al., “Mutations at the GABA receptor selectivity filter: a possible role for effective charges,”J. Physiol.548(2):527-540 (2003).
Wozney et al., “Novel Regulators of Bone Formation: Molecular Clones and Activities,”Science, 242(4885):1528-1534 (1988).
Wozney, “Bone Morphogenetic Proteins,”Progress in Growth Factor Research, 1:267-280 (1989).
Jelic et al., “Regeneration of Articular Cartilage Chondral Defects by Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in Sheep,”Growth Factors, 19:101-113 (2001).
Kirker-Head, “Potential applications and delivery strategies for bone morphogenetic proteins,”Advanced Drug Delivery Reviews, 43:65-92 (2000).
Simic et al., “Systemically Administered Bone Morphogenetic Protein-6 Restores Bone in Aged Ovariectomized Rats by Increasing Bone Formation and Suppressing Bone Resorption,”J. Biol. Chem., 281(35):25509-25521 (2006).
Urist, “Experimental Delivery Systems for Bone Morphogenetic Protein,”Encyclopedic Handbook of Biomaterials and Bioengineering, Wise et al. (eds.), vol. 2, Part A: Materials, pp. 1093-1133 (1995).
Weber et al., “Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres,”Int. J. Oral Maxillofac. Surg., 31:60-65 (2002).

Affiliated with

Also associated with

Rating

Mutants of bone morphogenetic proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutants of bone morphogenetic proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutants of bone morphogenetic proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3940571